EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis

Christine M Cheng iD

Annals of Pharmacotherapy · 13.07.2026

DOI: 10.1177/10600280261463225 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 13.07.2026. Verfasst von Christine M Cheng. Beteiligte Einrichtung: Drug Utilization Management, Stanford Health Care, Palo Alto, CA, USA. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To summarize the clinical evidence for zopapogene imadenovec-drba (Papzimeos, Precigen Inc) in the treatment of recurrent respiratory papillomatosis (RRP), address pharmacy-specific operational considerations for this drug and provide an overview of emerging human papillomavirus (HPV)-directed immunotherapies that may expand the pharmacist’s role in RRP management. Data Sources: PubMed, Scopus, Google Scholar, and ClinicalTrials.gov (through May 2026); prescribing information; treatment guidelines; AMCP Format 5.0 dossier; and FDA clinical review. Study Selection and Data Extraction: Efficacy and safety data were derived from the pivotal PRGN-2012-201 trial (NCT04724980). Pipeline therapies were identified from IPD Analytics. Data Synthesis: In the phase 1/2 PRGN-2012-201 trial (n = 35 at recommended dose), zopapogene imadenovec demonstrated a 51% complete response rate at 12 months (43% at 24 months), an objective response rate of 66%, and no serious treatment-related adverse events. INO-3107, a DNA immunotherapy under FDA review, has shown complete response rates from 28% to 50% by year 2. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Zopapogene imadenovec-drba is the first FDA-approved therapy for RRP, a condition historically managed through repeated surgical debulking. Off-label adjuvant therapies such as intralesional cidofovir, bevacizumab, and HPV vaccination have been used with variable efficacy.

Conclusions

The shift from primarily surgical management of RRP to HPV-directed immunotherapy creates an expanded role for pharmacists in high-cost drug stewardship (including formulary evaluation, manufacturer and payer engagement, and revenue cycle optimization), operational management (including procurement, ultra-cold storage, and biosafety handling), clinical monitoring, and patient education on a mechanistically novel therapy.

Schlagwörter

Stichwörter der Autor:innen

RRPformulary managementgene therapyhigh-cost drugimmunotherapyrecurrent respiratory papillomatosiszopapogene

Autor:innen und Institutionen

  • Drug Utilization Management, Stanford Health Care, Palo Alto, CA, USA.

ORCID-Profile: Christine M Cheng

Zitieren

APA

Cheng, C. M. (2026). Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261463225

Vancouver

Cheng CM. Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261463225

BibTeX
@article{Cheng2026,
  author = {Cheng, Christine M},
  title = {Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280261463225}
}
Kostenlos starten →